NTII Neurobiological Technologies (MM)

EMERYVILLE, Calif., Nov. 5 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NASDAQ:NTII), today announced that Paul E. Freiman, President and Chief Executive Officer, will present at the Rodman & Renshaw 10th Annual Healthcare Conference November 10 to 12 at the New York Palace Hotel. Mr. Freiman's presentation will take place at 3:15 p.m. (ET) on November 10. The presentation will be webcast and can be accessed by going to: http://investor.shareholder.com/ntii/events.cfm About Neurobiological Technologies, Inc. Neurobiological Technologies, Inc., (NASDAQ:NTII) is a biopharmaceutical company focused on developing novel, first-in-class agents for central nervous system conditions and other serious unmet medical needs. The Company's most advanced product candidate, Viprinex(TM) (ancrod), is in Phase 3 clinical testing as a novel investigational drug for the treatment of acute ischemic stroke. Viprinex has multiple mechanisms of action and is specifically designed to extend the time period that patients can be treated after the onset of a stroke. NTI also has early-stage development programs for Alzheimer's and Huntington's diseases, rights to receive payments on an approved drug for Alzheimer's disease and an investigational drug in Phase 3 trials for brain swelling. DATASOURCE: Neurobiological Technologies, Inc. CONTACT: Matthew M. Loar, CFO of Neurobiological Technologies, Inc., +1-510-595-6000 Web Site: http://www.ntii.com/

Copyright